

**PRESS RELEASE FROM NEUROPSYCHOPHARMACOLOGY**  
(<http://www.nature.com/npp/>)

This press release is copyrighted to the journal *Neuropsychopharmacology*. Its use is granted only for journalists and news media receiving it directly from the Nature Publishing Group.

**EMBARGO:**

**1600 London Time (GMT) / 1100 US Eastern time Wednesday 10 January**  
**0100 Japanese Time / 0300 Australian Eastern time Thursday 11 January**

**Wire services' stories must always carry the embargo time at the head of each item, and may not be sent out more than 24 hours before that time.**

**Solely for the purpose of soliciting informed comment on this paper, you may show it to independent specialists - but you must ensure in advance that they understand and accept the embargo conditions.**

A PDF of the paper mentioned on this release can be found in the relevant journal's section of <http://press.nature.com>. Press contacts for the *Nature* journals are listed at the end of this release.

**Warning: This document, and the NPG Academic Journal paper to which it refers, may contain information that is price sensitive (as legally defined, for example, in the UK Criminal Justice Act 1993 Part V) with respect to publicly quoted companies. Anyone dealing in securities using information contained in this document or in advanced copies of *Nature's* content may be guilty of insider trading under the US Securities Exchange Act of 1934.**

PLEASE CITE *NEUROPSYCHOPHARMACOLOGY* AND THE *NEUROPSYCHOPHARMACOLOGY* WEBSITE AS THE SOURCE OF THE FOLLOWING ITEM. IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO [www.nature.com/npp/](http://www.nature.com/npp/).

**[Inhalant abuse: 'Sniffing' toluene for a high](#)**

DOI: 10.1038/sj.npp.1301273

Toluene, a commonly abused toxic compound, is shown to stimulate dopamine release in specific regions of the rat brain known as drug reward pathways, according to research published online in *Neuropsychopharmacology* this week. Until now it has been unclear whether toluene affects reward centers in the brain, and where, so ultimately this knowledge could help in developing strategies to prevent and treat addiction to substances containing toluene.

Toluene is found in paint thinners, varnishes and even nail polish remover. Researchers from the University of Arizona and the National Institute of Drug Abuse (NIDA) demonstrate that toluene directly stimulates dopamine neurons causing dopamine release. Dopamine is a neurotransmitter and is released by reward centers in the brain causing a feeling of euphoria. The results suggest that the brain likely also interprets sniffing toluene as rewarding which can result in further abuse and possibly future use of other drugs.

Besides showing where in the brain toluene acts, the researchers also demonstrate that, surprisingly, toluene substances are most effective when used at low concentrations. Since toluene is rapidly absorbed in the brain, this might explain why the preferred mode of delivery is by "huffing" or "sniffing". Sniffing is frequently considered a harmless recreational or party drug but unlike other drugs, even a single session of inhaling the compound can disrupt heart rhythms

enough to cause cardiac arrest and lower oxygen levels enough to cause suffocation. Despite a decline in overall adolescent drug use since the late 90's, recreational use of inhalants is increasing. Inhalant abuse is now considered the fourth most abused drug among US teens according to NIDA. Because inhalants activate the same area of the brain that other drugs of abuse affect (e.g. cocaine and methamphetamines), future research will involve the investigation of their combined interactions on the brain.

**Author contact:**

Arthur C. Riegel (The Vollom Institute, Portland, OR, USA)

Tel: +1 503 494 4723, E-mail: [riegela@ohsu.edu](mailto:riegela@ohsu.edu)

**PRESS CONTACTS...**

*For media inquiries relating to editorial content/policy for the Journal Neuropsychopharmacology:*

Joyce-Rachel John (NPG Academic Journals, New York)

Tel: +1 212 726 9214; E-mail: [j.john@natureny.com](mailto:j.john@natureny.com)

*For media inquiries relating to embargo policy for the Journal Neuropsychopharmacology:*

Ruth Francis (Nature London)

Tel: +44 20 7843 4562; E-mail: [r.francis@nature.com](mailto:r.francis@nature.com)

*For media inquiries relating to the American College of Neuropsychopharmacology:*

Tel: +1 615 324 2360; E-mail: [acnp@acnp.org](mailto:acnp@acnp.org)

**About Nature Publishing Group**

Nature Publishing Group (NPG) is a division of Macmillan Publishers Ltd, dedicated to serving the academic, professional scientific and medical communities. NPG's flagship title, *Nature*, was first published in 1869. Other publications include *Nature* research journals, *Nature Reviews*, *Nature Clinical Practice* and a range of prestigious academic journals including society-owned publications. NPG also provides news content through [news@nature.com](mailto:news@nature.com) and scientific career information through *Naturejobs*.

NPG is a global company with headquarters in London and offices in New York, San Francisco, Washington DC, Boston, Tokyo, Paris, Munich, Hong Kong, Melbourne, Delhi, Mexico City and Basingstoke. For more information, please go to [www.nature.com](http://www.nature.com)